Clinical Trials Browser

Phase 2 × Unknown × relmacabtagene autoleucel × Clear all

NCT05590221 2024-01-08

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Phase 2 Unknown

Lymphoma, B-Cell